Related Experiment Videos
PUFA supplements and type 2 diabetes in the elderly.
A M Abbatecola1, W Evans, G Paolisso
1Scientific Direction, Italian National Research Center on Aging (INRCA), Ancona, Italy.
Current Pharmaceutical Design
|January 1, 2010
Summary
Increasing type 2 diabetes risk in older adults is linked to inactivity and high dietary fat. Omega-3 polyunsaturated fatty acids (PUFA) may lower risk and improve health outcomes, including cognitive function.
Area of Science:
- Nutrition Science
- Metabolic Disorders
- Geriatric Medicine
Background:
- Type 2 diabetes prevalence is rising, particularly in older adults, linked to physical inactivity and dietary fat.
- Dietary patterns, including n-3 polyunsaturated fatty acids (PUFA) and saturated/monounsaturated fats, influence type 2 diabetes risk.
- Elderly individuals with type 2 diabetes face risks of cognitive decline and physical disability.
Purpose of the Study:
- To review dietary fat intake patterns and their role in insulin resistance and type 2 diabetes.
- To examine the effects of PUFA supplementation on glucose metabolism, diabetic dyslipidemia, and cardiovascular disease.
- To explore potential benefits of PUFA supplementation for cognitive decline and physical disability in the elderly.
Main Methods:
- Literature review of epidemiological studies and clinical trials.
- Analysis of dietary fat intake, insulin resistance, and type 2 diabetes development.
- Evaluation of PUFA supplementation effects on metabolic markers and geriatric syndromes.
Main Results:
- Higher intake of total, saturated, and monounsaturated fats is associated with increased type 2 diabetes risk.
- n-3 PUFA consumption is linked to a lower incidence of type 2 diabetes.
- PUFA benefits extend to cardiovascular health and may impact cognitive and physical function in the elderly.
Conclusions:
- Dietary fat composition significantly impacts type 2 diabetes risk and progression.
- n-3 PUFA supplementation shows promise for managing type 2 diabetes and its complications.
- Further research into PUFA's role in preventing geriatric syndromes in diabetic elderly is warranted.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...